Jiangsu Hengrui Pharmaceuticals Receives Chinese Regulatory Nod to Begin Clinical Trials of 2 Medicines; Shares Rise 2%

MT Newswires Live

Jul 10

Jiangsu Hengrui Pharmaceuticals (HKG:1276) received Chinese regulatory approval to begin clinical trials of two experimental medicines, according to Hong Kong bourse filings Wednesday.

Shares of the pharma company rose over 2% in morning trade Thursday.

The company said it secured the National Medical Products Administration's nod to study SHR-2173 as a treatment for primary membranous nephropathy, an autoimmune kidney disease.

Meanwhile, the regulator also approved Jiangsu's request to evaluate HRS-9821 in chronic obstructive pulmonary disease, a lung condition.

Clinical trials for both drugs will begin in the near future, the firm said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2550699346"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2550699346\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2550699346?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-10 11:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2550699346","market":"us","top_or_hot":-1,"title":"Jiangsu Hengrui Pharmaceuticals Receives Chinese Regulatory Nod to Begin Clinical Trials of 2 Medicines; Shares Rise 2%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/600276\">Jiangsu Hengrui</a> Pharmaceuticals (HKG:1276) received Chinese regulatory approval to begin clinical trials of two experimental medicines, according to <a href=\"https://laohu8.com/S/HKRHF\">Hong Kong</a> bourse filings Wednesday.</p><p>Shares of the pharma company rose over 2% in morning trade Thursday.</p><p>The company said it secured the <a href=\"https://laohu8.com/S/NHLD\">National</a> Medical Products Administration's nod to study SHR-2173 as a treatment for primary membranous nephropathy, an autoimmune kidney disease.</p><p>Meanwhile, the regulator also approved Jiangsu's request to evaluate HRS-9821 in chronic obstructive pulmonary disease, a lung condition.</p><p>Clinical trials for both drugs will begin in the near future, the firm said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jiangsu Hengrui Pharmaceuticals Receives Chinese Regulatory Nod to Begin Clinical Trials of 2 Medicines; Shares Rise 2%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJiangsu Hengrui Pharmaceuticals Receives Chinese Regulatory Nod to Begin Clinical Trials of 2 Medicines; Shares Rise 2%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-07-10 11:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/600276\">Jiangsu Hengrui</a> Pharmaceuticals (HKG:1276) received Chinese regulatory approval to begin clinical trials of two experimental medicines, according to <a href=\"https://laohu8.com/S/HKRHF\">Hong Kong</a> bourse filings Wednesday.</p><p>Shares of the pharma company rose over 2% in morning trade Thursday.</p><p>The company said it secured the <a href=\"https://laohu8.com/S/NHLD\">National</a> Medical Products Administration's nod to study SHR-2173 as a treatment for primary membranous nephropathy, an autoimmune kidney disease.</p><p>Meanwhile, the regulator also approved Jiangsu's request to evaluate HRS-9821 in chronic obstructive pulmonary disease, a lung condition.</p><p>Clinical trials for both drugs will begin in the near future, the firm said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01276","symbol_name":"恒瑞医药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2550699346","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2550699346","pubTimestamp":1752118131,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Jiangsu Hengrui Pharmaceuticals  received Chinese regulatory approval to begin clinical trials of two experimental medicines, according to Hong Kong bourse filings Wednesday.Shares of the pharma company rose over 2% in morning trade Thursday.The company said it secured the National Medical Products Administration's nod to study SHR-2173 as a treatment for primary membranous nephropathy, an autoimmune kidney disease.Meanwhile, the regulator also approved Jiangsu's request to evaluate HRS-9821 in chronic obstructive pulmonary disease, a lung condition.Clinical trials for both drugs will begin in the near future, the firm said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01276":"恒瑞医药","BK1191":"制药","MDCO":"麦迪逊医药"},"translate_title":"江苏恒瑞医药获得中国监管机构批准开始2种药物的临床试验；股价上涨2%","themeId":"8247f18167aa0848b7f3edba598e3f11","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01276":0.9,"MDCO":1},"content_text":"Jiangsu Hengrui Pharmaceuticals (HKG:1276) received Chinese regulatory approval to begin clinical trials of two experimental medicines, according to Hong Kong bourse filings Wednesday.Shares of the pharma company rose over 2% in morning trade Thursday.The company said it secured the National Medical Products Administration's nod to study SHR-2173 as a treatment for primary membranous nephropathy, an autoimmune kidney disease.Meanwhile, the regulator also approved Jiangsu's request to evaluate HRS-9821 in chronic obstructive pulmonary disease, a lung condition.Clinical trials for both drugs will begin in the near future, the firm said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}